نتایج جستجو برای: cell vaccines

تعداد نتایج: 1721750  

2013
Mark D. Mannie Alan D. Curtis, II

Tolerogenic vaccines represent a new class of vaccine designed to re-establish immunological tolerance, restore immune homeostasis, and thereby reverse autoimmune disease. Tolerogenic vaccines induce long-term, antigen-specific, inhibitory memory that blocks pathogenic T cell responses via loss of effector T cells and gain of regulatory T cell function. Substantial advances have been realized i...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2005
Sheng-Hong Tseng Yun Chen Chun-Jung Chang Kuo-Feng Tai Swei-Ming Lin Lih-Hwa Hwang

PURPOSE To evaluate antitumor effects on intracerebral gliomas of genetically engineered tumor vaccines expressing granulocyte-macrophage colony-timulating factor (GM-CSF), B7.1, or both (combination). EXPERIMENTAL DESIGN A rat glioma cell line, RT-2, was engineered with a retroviral vector to express GM-CSF, B7.1, or combination. Tumorigenicity of engineered cells and therapeutic effects of ...

2011
Shigeo Koido Sadamu Homma Akitaka Takahara Yoshihisa Namiki Hideo Komita Eijiro Nagasaki Masaki Ito Keisuke Nagatsuma Kan Uchiyama Kenichi Satoh Toshifumi Ohkusa Jianlin Gong Hisao Tajiri

Although dendritic cell (DC)- based cancer vaccines induce effective antitumor activities in murine models, only limited therapeutic results have been obtained in clinical trials. As cancer vaccines induce antitumor activities by eliciting or modifying immune responses in patients with cancer, the Response Evaluation Criteria in Solid Tumors (RECIST) and WHO criteria, designed to detect early e...

Journal: :The oncologist 2006
Christopher P Tarassoff Philip M Arlen James L Gulley

Prostate cancer is the most common, noncutaneous cancer for men in the U.S., leading to more than 30,000 deaths a year. Vaccines for prostate cancer, which for several years have been shown to generate immunologic responses, are beginning to show significant clinical promise. At present, numerous therapeutic options are being investigated, including autologous and allogeneic whole-tumor cell va...

2007

Introduction A Q fever vaccine for humans is not currently licensed in the UK. Globally there are two broad types of vaccine currently in use or undergoing research: formalin-inactivated whole-cell vaccines such as the commercially available Q-vax in Australia, and acellular vaccines, such as trichloroacetic acid extracted (TCA) and chloroform-methanol residue (CMR) vaccines, developed in forme...

2010
Petr G. Lokhov Elena E. Balashova

A recent advance in anti-cancer therapies has been the use of cancer cells to develop vaccines. However, immunization with cancer cell-based vaccines has not resulted in significant long-term therapeutic benefits. A possible reason for this is that while cancer cells provide surface antigens that are targets for a desired immune response, they also contain a high abundance of housekeeping prote...

Journal: :Journal of Immunology 2023

Abstract Cellular vaccines, primarily monocyte-derived dendritic cells (MoDC), have recently been realized as therapeutic cancer vaccines with modest clinical efficacy. Understanding the mechanism by which these lead to antigen presentation is key improving their potency. A significant advancement was discovery that MoDC do not directly present antigen, but instead rely on endogenous for presen...

2008
Michael P Gustafson Keith L Knutson Allan B Dietz

Malignant gliomas are the most common and aggressive form of brain tumors. Current therapy consists of surgical resection, followed by radiation therapy and concomitant chemotherapy. Despite these treatments, the prognosis for patients is poor. As such, investigative therapies including tumor vaccines have targeted this devastating condition. Recent clinical trials involving immunotherapy, spec...

Journal: :The Journal of clinical investigation 2017
Zinaida Polonskaya Shenglou Deng Anita Sarkar Lisa Kain Marta Comellas-Aragones Craig S McKay Katarzyna Kaczanowska Marie Holt Ryan McBride Valle Palomo Kevin M Self Seth Taylor Adriana Irimia Sanjay R Mehta Jennifer M Dan Matthew Brigger Shane Crotty Stephen P Schoenberger James C Paulson Ian A Wilson Paul B Savage M G Finn Luc Teyton

Vaccines targeting glycan structures at the surface of pathogenic microbes must overcome the inherent T cell-independent nature of immune responses against glycans. Carbohydrate conjugate vaccines achieve this by coupling bacterial polysaccharides to a carrier protein that recruits heterologous CD4 T cells to help B cell maturation. Yet they most often produce low- to medium-affinity immune res...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید